Goodman Financial Corp grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 432,271 shares of the biopharmaceutical company's stock after purchasing an additional 22,609 shares during the quarter. Pfizer makes up about 2.4% of Goodman Financial Corp's portfolio, making the stock its 27th biggest holding. Goodman Financial Corp's holdings in Pfizer were worth $11,468,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter valued at $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Pfizer Stock Down 0.6 %
Shares of Pfizer stock traded down $0.15 during trading hours on Monday, hitting $26.13. The company had a trading volume of 37,863,216 shares, compared to its average volume of 36,651,219. The company's 50-day moving average is $26.15 and its two-hundred day moving average is $27.02. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $148.21 billion, a P/E ratio of 18.53, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have issued reports on PFE. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Bank of America restated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.
Get Our Latest Analysis on PFE
Insider Activity
In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
